Back to search

Article

ARGX-119, a therapeutic agonist antibody targeting MuSK

2024-07-22

Abstract excerpt

ARGX-119 is a novel, humanized, agonist monoclonal SIMPLE Antibody™ specific for muscle-specific kinase (MuSK) that is being developed for treatment of patients with neuromuscular diseases. ARGX-119 is the first monoclonal antibody (mAb) that binds with high affinity to the Frizzled-like domain of human, non-human primate, rat and mouse MuSK, without off-target binding, making it suitable for clinical development....

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
de81ccf1-2de7-5295-96b1-1b31649108a2
DOI
10.1101/2024.07.18.604166
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
ARGX-119, a therapeutic agonist antibody targeting MuSKDOI 10.1101/2024.07.18.604166
Patient-specific therapeutic benefit of MuSK agonist antibody ARGX-119 in MuSK myasthenia gravis passive transfer modelsSemantic proximity
Gene-specific response to MuSK agonist antibody in the treatment of Congenital Myasthenic SyndromesSemantic proximity
Mechanism of disease and therapeutic rescue of Dok7 congenital myasthenia.Semantic proximity
Dose escalation pre-clinical trial of novel DOK7-AAV in mouse model of DOK7 congenital myastheniaSemantic proximity
The MuSK agonist antibody protects the neuromuscular junction and extends the lifespan in C9orf72-ALS miceSemantic proximity
Development and characterization of agonistic antibodies targeting the Ig-like 1 domain of MuSKSemantic proximity
MuSK antibodies differently affect the MuSK signaling cascade depending on valency and epitope specificitySemantic proximity
Therapy with eculizumab for patients with CD59 p.Cys89Tyr mutation.Semantic proximity
A HUMANIZED FCRN TRANSGENIC MOUSE FOR PRECLINICAL PHARMACOKINETICS STUDIESSemantic proximity
Dok-7/MuSK signaling and a congenital myasthenic syndrome.Semantic proximity
Optimization of a Glucagon-Like Peptide 1 Receptor Antagonist Antibody for Treatment of Hyperinsulinism.Semantic proximity
Translational Pharmacokinetic/Pharmacodynamic Analysis of MYO‐029 Antibody for Muscular DystrophySemantic proximity
Select a neighboring publication to make it the new centre.